Literature DB >> 17464308

Intraocular use of rituximab.

A S Kitzmann1, J S Pulido, B G Mohney, K H Baratz, T Grube, R J Marler, M J Donaldson, B P O'Neill, P B Johnston, K M Johnson, L E Dixon, D R Salomao, J D Cameron.   

Abstract

PURPOSE: To evaluate the toxicity of 1 mg of intraocular rituximab and to present a small case-series of patients treated with intravitreal rituximab.
METHODS: Rituximab (1 mg/0.1 ml) was injected in the vitreous of one eye of three Dutch-belted rabbits. Two animals were injected with balanced salt solution as controls. At 1 month the rabbits were killed and the eyes examined by light microscopy. Three patients (five eyes) with intraocular lymphoma were also treated with a 1 mg injection of rituximab.
RESULTS: The treated rabbit eyes and the control eyes showed no light microscopic evidence of ocular toxicity at 1 month following injection. The five human eyes of three patients have shown no evidence of intraocular toxicity with a median follow-up time of 3.6 months (range 2.0-6.4 months). One patient received a total of four injections in the right eye and three injections in the left eye.
CONCLUSION: Intravitreal rituximab at a dose of 1 mg does not appear to cause toxicity in rabbit eyes and in the five eyes of three patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17464308     DOI: 10.1038/sj.eye.6702804

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  22 in total

Review 1.  Ocular vasculitis.

Authors:  Gabriela M Espinoza; Ankit Desai; Levent Akduman
Journal:  Curr Rheumatol Rep       Date:  2013-09       Impact factor: 4.592

2.  Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy.

Authors:  James L Rubenstein; Patrick A Treseler; Paul J Stewart
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

Review 3.  New approaches in primary central nervous system lymphoma.

Authors:  Eleanor Fraser; Katherine Gruenberg; James L Rubenstein
Journal:  Chin Clin Oncol       Date:  2015-03

Review 4.  Diagnostic vitrectomy for primary intraocular lymphoma: when, why, how?

Authors:  Cindy S Hwang; Steven Yeh; Chris S Bergstrom
Journal:  Int Ophthalmol Clin       Date:  2014

Review 5.  The Challenge of Primary Central Nervous System Lymphoma.

Authors:  Julia Carnevale; James L Rubenstein
Journal:  Hematol Oncol Clin North Am       Date:  2016-12       Impact factor: 3.722

Review 6.  Intraocular lymphoma.

Authors:  Li-Juan Tang; Chang-Lin Gu; Ping Zhang
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

7.  Efficacy and Complications of Intravitreal Rituximab Injection for Treating Primary Vitreoretinal Lymphoma.

Authors:  Noriyasu Hashida; Nobuyuki Ohguro; Kohji Nishida
Journal:  Transl Vis Sci Technol       Date:  2012-10-22       Impact factor: 3.283

8.  Association between ocular findings and preventive therapy with onset of central nervous system involvement in patients with primary vitreoretinal lymphoma.

Authors:  Noriyasu Hashida; Kei Nakai; Norimitsu Saitoh; Kohji Nishida
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-02-19       Impact factor: 3.117

9.  Ifosfamide or trofosfamide in patients with intraocular lymphoma.

Authors:  Kristoph Jahnke; Eckhard Thiel; Nikolaos E Bechrakis; Gregor Willerding; Dale F Kraemer; Lars Fischer; Agnieszka Korfel
Journal:  J Neurooncol       Date:  2008-12-20       Impact factor: 4.130

10.  How I treat CNS lymphomas.

Authors:  James L Rubenstein; Neel K Gupta; Gabriel N Mannis; Amanda K Lamarre; Patrick Treseler
Journal:  Blood       Date:  2013-08-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.